company background image
DVA

DaVitaNYSE:DVA Stock Report

Market Cap

US$9.9b

7D

-5.6%

1Y

-11.8%

Updated

30 Nov, 2021

Data

Company Financials +
DVA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance3/6
Financial Health3/6
Dividends0/6

DVA Stock Overview

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD).

DaVita Competitors

Cigna

NYSE:CI

US$66.2b

UnitedHealth Group

NYSE:UNH

US$414.3b

Anthem

NYSE:ANTM

US$101.0b

Humana

NYSE:HUM

US$55.0b

Price History & Performance

Summary of all time highs, changes and price drops for DaVita
Historical stock prices
Current Share PriceUS$96.91
52 Week HighUS$136.48
52 Week LowUS$96.75
Beta1.19
1 Month Change-6.13%
3 Month Change-25.89%
1 Year Change-11.78%
3 Year Change45.99%
5 Year Change51.16%
Change since IPO2,278.15%

Recent News & Updates

Oct 29
DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Oct 14
Does DaVita (NYSE:DVA) Deserve A Spot On Your Watchlist?

Does DaVita (NYSE:DVA) Deserve A Spot On Your Watchlist?

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Shareholder Returns

DVAUS HealthcareUS Market
7D-5.6%-0.4%-0.9%
1Y-11.8%20.7%23.3%

Return vs Industry: DVA underperformed the US Healthcare industry which returned 19.1% over the past year.

Return vs Market: DVA underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is DVA's price volatile compared to industry and market?
DVA volatility
DVA Average Weekly Movement4.6%
Healthcare Industry Average Movement6.3%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: DVA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: DVA's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199467,000Javier Rodriguezhttps://www.davita.com

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

DaVita Fundamentals Summary

How do DaVita's earnings and revenue compare to its market cap?
DVA fundamental statistics
Market CapUS$9.88b
Earnings (TTM)US$984.38m
Revenue (TTM)US$11.58b

10.0x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DVA income statement (TTM)
RevenueUS$11.58b
Cost of RevenueUS$7.97b
Gross ProfitUS$3.61b
ExpensesUS$2.63b
EarningsUS$984.38m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)9.66
Gross Margin31.18%
Net Profit Margin8.50%
Debt/Equity Ratio313.8%

How did DVA perform over the long term?

See historical performance and comparison

Valuation

Is DaVita undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DVA ($96.91) is trading below our estimate of fair value ($208.16)

Significantly Below Fair Value: DVA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DVA is good value based on its PE Ratio (10x) compared to the US Healthcare industry average (21.5x).

PE vs Market: DVA is good value based on its PE Ratio (10x) compared to the US market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: DVA is poor value based on its PEG Ratio (1.9x)


Price to Book Ratio

PB vs Industry: DVA is overvalued based on its PB Ratio (8.6x) compared to the US Healthcare industry average (2.9x).


Future Growth

How is DaVita forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

5.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DVA's forecast earnings growth (5.2% per year) is above the savings rate (2%).

Earnings vs Market: DVA's earnings (5.2% per year) are forecast to grow slower than the US market (14.3% per year).

High Growth Earnings: DVA's earnings are forecast to grow, but not significantly.

Revenue vs Market: DVA's revenue (4.1% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: DVA's revenue (4.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DVA's Return on Equity is forecast to be very high in 3 years time (113%).


Past Performance

How has DaVita performed over the past 5 years?

-5.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DVA has high quality earnings.

Growing Profit Margin: DVA's current net profit margins (8.5%) are higher than last year (7.2%).


Past Earnings Growth Analysis

Earnings Trend: DVA's earnings have declined by 5.9% per year over the past 5 years.

Accelerating Growth: DVA's earnings growth over the past year (18.3%) exceeds its 5-year average (-5.9% per year).

Earnings vs Industry: DVA earnings growth over the past year (18.3%) underperformed the Healthcare industry 32.5%.


Return on Equity

High ROE: Whilst DVA's Return on Equity (44.2%) is outstanding, this metric is skewed due to their high level of debt.


Financial Health

How is DaVita's financial position?


Financial Position Analysis

Short Term Liabilities: DVA's short term assets ($3.8B) exceed its short term liabilities ($2.4B).

Long Term Liabilities: DVA's short term assets ($3.8B) do not cover its long term liabilities ($12.5B).


Debt to Equity History and Analysis

Debt Level: DVA's net debt to equity ratio (274.9%) is considered high.

Reducing Debt: DVA's debt to equity ratio has increased from 145% to 313.8% over the past 5 years.

Debt Coverage: DVA's debt is well covered by operating cash flow (21.8%).

Interest Coverage: DVA's interest payments on its debt are well covered by EBIT (6.6x coverage).


Balance Sheet


Dividend

What is DaVita current dividend yield, its reliability and sustainability?

2.30%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Javier Rodriguez (50 yo)

2.42yrs

Tenure

US$73,432,365

Compensation

Mr. Javier J. Rodriguez serves as Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rodrig...


CEO Compensation Analysis

Compensation vs Market: Javier's total compensation ($USD73.43M) is above average for companies of similar size in the US market ($USD11.11M).

Compensation vs Earnings: Javier's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: DVA's management team is seasoned and experienced (5.5 years average tenure).


Board Members

Experienced Board: DVA's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DaVita Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: DaVita Inc.
  • Ticker: DVA
  • Exchange: NYSE
  • Founded: 1994
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$9.875b
  • Shares outstanding: 101.90m
  • Website: https://www.davita.com

Number of Employees


Location

  • DaVita Inc.
  • 2000 16th Street
  • Denver
  • Colorado
  • 80202
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 00:10
End of Day Share Price2021/11/29 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.